PDF(Pubmed)
Abstract：
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and its morbidity is increasing worldwide due to increasing prevalence. Metabolic reprogramming has been recognized as a hallmark of cancer and serves a role in cancer progression. Glucose, lipids and amino acids are three major components whose altered metabolism can directly affect the energy production of cells, including liver cancer cells. Nutrients and energy are indispensable for the growth and proliferation of cancer cells, thus altering the metabolism of hepatoma cells can inhibit the progression of HCC. The present review summarizes recent studies on tumour regulatory molecules, including numerous noncoding RNAs, oncogenes and tumour suppressors, which regulate the metabolic activities of glucose, lipids and amino acids by targeting key enzymes, signalling pathways or interactions between the two. These regulatory molecules can regulate the rapid proliferation of cancer cells, tumour progression and treatment resistance. It is thought that these tumour regulatory factors may serve as therapeutic targets or valuable biomarkers for HCC, with the potential to mitigate HCC drug resistance. Furthermore, the advantages and disadvantages of metabolic inhibitors as a treatment approach for HCC, as well as possible solutions are discussed, providing insights for developing more effective treatment strategies for HCC.
摘要：
肝细胞癌（HCC）是最常见的原发性肝脏恶性肿瘤，由于患病率的增加，其发病率在全球范围内也在增加。代谢重编程已被认为是癌症的标志，并在癌症进展中起作用。葡萄糖,脂质和氨基酸是三种主要成分，它们的代谢改变可以直接影响细胞的能量产生，包括肝癌细胞.营养和能量对于癌细胞的生长和增殖是不可或缺的，因此改变肝癌细胞的代谢可以抑制肝癌的进展。本综述总结了最近对肿瘤调节分子的研究，包括许多非编码RNA，癌基因和肿瘤抑制基因，调节葡萄糖的代谢活动，通过靶向关键酶的脂质和氨基酸，信号通路或两者之间的相互作用。这些调节分子可以调节癌细胞的快速增殖，肿瘤进展和治疗抵抗。据认为，这些肿瘤调节因子可作为肝癌的治疗靶点或有价值的生物标志物。具有减轻HCC耐药性的潜力。此外，代谢抑制剂作为肝癌治疗方法的优缺点，以及可能的解决方案进行了讨论，为开发更有效的HCC治疗策略提供见解。
